• Home
  •  / Northwest Biotherapeutics

Northwest Biotherapeutics

OverviewSuggest Edit

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

TypePublic
Founded1998
HQBethesda, MD, USMap
Websitenwbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)17(+22%)
Revenue (FY, 2020)$1.3 M(-46%)
Share Price (Jul 2021)$1.3(-3%)
Cybersecurity ratingAMore

Key People/Management at Northwest Biotherapeutics

Les Goldman

Les Goldman

Senior Vice President, Business Development

Northwest Biotherapeutics Office Locations

Northwest Biotherapeutics has an office in Bethesda
Bethesda, MD, US (HQ)
4800 Montgomery Ln
Show all (1)

Northwest Biotherapeutics Financials and Metrics

Northwest Biotherapeutics Revenue

Northwest Biotherapeutics's revenue was reported to be $1.29 m in FY, 2020
USD

Revenue (Q1, 2021)

239.0k

Net income (Q1, 2021)

(4.1m)

EBIT (Q1, 2021)

(19.6m)

Market capitalization (15-Jul-2021)

1.1b

Closing stock price (15-Jul-2021)

1.3

Cash (31-Mar-2021)

7.5m

EV

1.1b
Northwest Biotherapeutics's current market capitalization is $1.1 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

10.0k772.0k809.0k1.5m1.7m623.0k336.0k412.0k2.4m1.3m

Cost of goods sold

Gross profit

10.0k772.0k809.0k

Gross profit Margin, %

100%100%100%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

10.0k330.0k120.0k137.0k400.0k582.0k194.0k391.0k291.0k236.0k157.0k159.0k68.0k88.0k148.0k132.0k278.0k453.0k339.0k581.0k593.0k570.0k2.0k239.0k

Cost of goods sold

Gross profit

10.0k330.0k120.0k137.0k

Gross profit Margin, %

100%100%100%100%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.0k7.3m18.5m13.4m21.8m6.2m117.0k22.2m372.0k10.0m

Prepaid Expenses

94.0k112.0k147.0k387.0k1.4m1.0m1.3m1.6m2.8m5.5m

Current Assets

118.0k7.5m18.6m14.6m24.1m7.9m1.4m23.8m3.2m15.5m

PP&E

78.0k95.0k83.0k40.0m46.2m315.0k169.0k108.0k281.0k1.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

6.7m1.6m37.0k430.0k111.0k373.0k2.0m2.9m12.2m8.9m1.4m3.2m19.2m5.4m11.7m2.1m802.0k1.8m22.0k1.1m198.0k1.6m248.0k16.3m6.7m2.0m764.0k6.0m9.3m7.5m

Accounts Receivable

195.0k

Prepaid Expenses

69.0k170.0k79.0k260.0k186.0k39.0k363.0k138.0k147.0k177.0k167.0k666.0k978.0k950.0k1.1m1.5m785.0k923.0k797.0k1.1m931.0k838.0k870.0k2.3m2.2m2.6m2.8m2.3m2.9m5.7m

Current Assets

6.8m1.8m116.0k885.0k297.0k412.0k2.3m7.5m12.4m12.4m1.6m4.7m21.2m7.1m13.5m4.5m2.3m3.2m819.0k2.1m1.1m2.4m1.1m18.6m8.9m4.6m3.6m8.2m12.2m13.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(32.8m)(67.3m)(65.8m)(135.6m)(114.7m)(80.2m)(73.1m)(35.8m)(20.3m)(529.8m)

Depreciation and Amortization

10.0k14.0k11.0k11.0k56.0k189.0k439.0k1.3m21.0k87.0k

Accounts Payable

1.4m577.0k766.0k5.0m3.9m1.0m501.0k(436.0k)30.0k1.7m

Cash From Operating Activities

(14.7m)(22.8m)(37.8m)(54.6m)(78.6m)(55.7m)(36.5m)(34.6m)(31.9m)(32.1m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(20.7m)(20.3m)(10.2m)(20.3m)(36.8m)(14.4m)(26.0m)(48.9m)(46.0m)(71.9m)(92.9m)(46.4m)(113.3m)(90.7m)(6.1m)(20.3m)(49.5m)(12.6m)(22.9m)(46.1m)(21.5m)(42.7m)(30.1m)(20.9m)(20.7m)(27.0m)2.7m(55.2m)(249.5m)(4.1m)

Depreciation and Amortization

4.0k6.0k2.0k4.0k10.0k3.0k6.0k9.0k3.0k6.0k352.0k3.0k15.0k44.0k13.0k80.0k135.0k56.0k100.0k141.0k365.0k722.0k1.1m2.0k8.0k16.0k14.0k16.0k33.0k68.0k

Accounts Payable

680.0k1.1m2.0m5.4m10.5m299.0k1.0m1.1m277.0k1.4m3.7m(378.0k)2.2m7.1m(3.1m)628.0k1.7m514.0k3.2m4.4m(628.0k)857.0k4.5m(65.0k)(742.0k)62.0k1.2m2.1m986.0k876.0k

Cash From Operating Activities

(5.0m)(10.2m)(3.5m)(8.4m)(14.5m)(7.1m)(15.3m)(23.2m)(10.6m)(27.5m)(36.0m)(17.6m)(44.7m)(56.5m)(17.6m)(31.8m)(41.6m)(12.3m)(16.0m)(21.7m)(4.8m)(16.4m)(20.4m)(9.8m)(19.4m)(25.9m)(7.5m)(13.9m)(21.9m)(13.2m)
show all
USDQ2, 2011

Financial Leverage

-0.2 x
Show all financial metrics

Northwest Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

Northwest Biotherapeutics Online and Social Media Presence

Northwest Biotherapeutics's Trends

Embed Graph

Northwest Biotherapeutics Company Culture

  • CEO Rating

    F

    50/100

  • Compensation

    F

    10/100

Learn more on Comparably

Northwest Biotherapeutics News and Updates

May 12, 2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

BETHESDA, Md., May 12, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to …
May 12, 2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston,...
October 05, 2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

BETHESDA, Md., Oct. 5, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been...
July 24, 2020

Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases

BETHESDA, Md., July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's...

Northwest Biotherapeutics Blogs

May 12, 2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Application Submitted to MHRA for Certification of Sawston Facility BETHESDA, Md., May 12, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company deve... Th…
March 16, 2021

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparati…
September 01, 2020

Northwest Biotherapeutics Acquires Flaskworks: Breakthrough Automation Technology For Cell Therapy Products To Enable Scale-Up of Production Volumes and Reduction of Production Costs

BETHESDA, Md., September 1, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system t... Th…
August 27, 2020

NW Bio Accelerating Sawston Plant Phase I Buildout: Construction Crews Working Double Shifts To Accelerate Completion Despite COVID Effects

BETHESDA, Md., August 27, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing preparations and planning as ... Th…
August 21, 2020

Northwest Biotherapeutics Announces $5 Million Financing: Non-Dilutive Debt; No Amortization For 7 Months; Maturity of 21 Months

BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L fo... Th…
August 19, 2020

NW Bio Announces Completion of Further Data Gathering For Phase III Trial

BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L fo... Th…
Show more

 Northwest Biotherapeutics Frequently Asked Questions

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1998.

  • Who are Northwest Biotherapeutics key executives?

    Northwest Biotherapeutics's key executives are Les Goldman.

  • How many employees does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 17 employees.

  • What is Northwest Biotherapeutics revenue?

    Latest Northwest Biotherapeutics annual revenue is $1.3 m.

  • What is Northwest Biotherapeutics revenue per employee?

    Latest Northwest Biotherapeutics revenue per employee is $75.9 k.

  • Who are Northwest Biotherapeutics competitors?

    Competitors of Northwest Biotherapeutics include Stingray Therapeutics, CNS Pharmaceuticals and Moleculin Biotech.

  • Where is Northwest Biotherapeutics headquarters?

    Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.

  • Where are Northwest Biotherapeutics offices?

    Northwest Biotherapeutics has an office in Bethesda.

  • How many offices does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 1 office.